modelNortriptyline
Extends from Pharmacolibrary.Drugs.ATC.N.N06AA10.
Information
| name: | Nortriptyline | |
| ATC code: | N06AA10 | route: | oral |
| compartments: | 1 | |
| dosage: | 75 | mg |
| volume of distribution: | 15.9 | L |
| clearance: | 22.9 | L/hr |
| other parameters in model implementation | ||
Nortriptyline is a tricyclic antidepressant primarily used in the treatment of major depressive disorder and sometimes for chronic neuropathic pain. It is an active metabolite of amitriptyline and is approved in many countries, including the US and UK, for clinical use, though newer antidepressants are often preferred due to a better side effect profile.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.
References
Jerling, M, et al., & Mallet, A (1994). Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. British journal of clinical pharmacology 38(5) 453–462. DOI:10.1111/j.1365-2125.1994.tb04382.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/7893588
Koh, A, et al., & Lim, HS (2019). Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. Journal of clinical pharmacology 59(4) 532–540. DOI:10.1002/jcph.1344 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30452773
Yue, QY, et al., & Sjöqvist, F (1998). Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clinical pharmacology and therapeutics 64(4) 384–390. DOI:10.1016/S0009-9236(98)90069-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9797795
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)